NeutralLOW severityHealthcare & Pharma61d ago

Jasper Therapeutics at H.C. Wainwright: cash and catalysts

Jasper Therapeutics at H.C. Wainwright: cash and catalysts — $JSPR one-month chart
$JSPR daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about JSPR. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · jasper therapeuticsEvent risk Low

Nothing reported about jasper therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 112% a year
Now $11.77Week $9.92–$13.62 (±15.7%)Month $7.98–$15.56 (±32.2%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
  • How the stock is trading: $JSPR -13.96% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.

Where the stock stands

Jasper Therapeutics ($JSPR) plunged 13.96% to $11.77 in the latest session. Over the past month it is down 17.7%. That leaves it 84% below its 52-week high of $72.60 and 25% above its low of $9.45, close to the bottom of its range. It has been a volatile year: the high was 7.7 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Nov 16, 2026), $JSPR lost $144.5M over the quarter to Sep 30, 2026 on revenue of $8.0M. Operations used $27.0M of cash over the nine months to Sep 30, 2026 — about $3.0M a month — against $135.3M in cash on Sep 30, 2026. At that pace the cash covers about 3.8 years. Total liabilities were $20.9M against $135.3M of cash on Sep 30, 2026. Figures are as filed with the SEC; the $JSPR page has the full statements.

How much coverage it is getting

This story is more than a month old. Since then Wook has filed one newer story on Jasper Therapeutics, published this week. It reads neutral.

The bigger picture

In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $JSPR page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $JSPR: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on September 16, 2026. $JSPR has moved -32.47% ($17.43 to $11.77). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy